bit.bio raised $25 million in a Series D to scale its human cell models at a time when demand for more predictive, industry-standard cell systems is accelerating. The UK biotech positions the funding to expand capacity and strengthen its platform for drug discovery workflows. The round reflects a continued shift away from purely generic cell models toward human-relevant systems that can better anticipate efficacy and safety signals earlier. For drug developers, the promise is improved screening fidelity and reduced reliance on late-stage attrition. As cell modeling becomes more central to discovery pipelines, additional capital is likely to translate into platform expansion, tooling, and services that support broader adoption across therapeutic areas.